About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
https://www.soho2019.com/
Hodgkin Lymphoma
Multiple Myeloma
Chronic Lymphocytic Leukemia
Meet The Professor Sessions
Chronic Myeloid Leukemia
Myeloproliferative Neoplasms
Breakfast With The Expert
Independent Satellite Symposium
Plenary Sessions
Evolving Practices in AML: A Case-based Guide to New and Emerging Treatment Options
Acute Lymphoblastic Leukemia
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Indolent B-cell Lymphoma
Mantle Cell Lymphoma
Aggressive B-cell Lymphoma
T-cell Lymphoma
Cellular Therapy
Next Questions
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
K
Integrative Sequencing of Myeloproliferative Neoplasms: RAS Pathway Mutations May Contribute to Aggressive Disease Behaviour and Potential Target for Future Therapy
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Kristen M. Pettit
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Kristen M. Pettit
4 views
November 18, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Myeloproliferative Neoplasms
13:43
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
MPN State of the Art Update: Stem Cell Niche
Feat.
R. Kralovics
13:00
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Primer on Chronic Neutrophilic Leukemia and Atypical CML Diagnosis a…
Feat.
U. Borate
17:33
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Identifying and Treating “Progression” in Myelofibrosis: Identificat…
Feat.
P. Bose
15:55
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Evolution of Transplant Approaches in MPN: Optional Conditioning Reg…
Feat.
D. Snyder
11:36
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
A New Way Forward w/ Immunogenicity of MPN: Mutant CALR Is Neoantige…
Feat.
R. Kralovics
08:06
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Fedratinib Induces Spleen Responses and Reduces Symptom Burden in MP…
Feat.
R. Mesa
08:51
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Integrative Sequencing of Myeloproliferative Neoplasms: RAS Pathway …
Feat.
K. Pettit
